Arriva Pharmaceuticals, Inc.   Report issue

For profit Phase 2
Founded: Alameda CA United States (1997)
Status: Defunct (2002)

Organization Overview

First Clinical Trial
2003
NCT00161707
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

alpha-1 antitrypsin (Prolastin) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

alpha 1-Antitrypsin Deficiency (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1